Specialty chemicals and biologics supplier SAFC has inked an agreement with CrystalGenomics to develop active pharmaceutical ingredients (APIs) for non-steroidal anti-inflammatory drugs (NSAID).
The agreement reflects SAFC's pre-formulation services contract into the South Korean pharmaceutical market.
As part of the agreement, CrystalGenomics will use UK-based SAFC's Pharmorphix Pre-formulation Technology services to understand the physical properties of APIs.
The services are also expected to help in selecting optimal crystallization processes, ensure batch-to-batch consistency in manufacturing and also to maintain efficacy and patient safety.
SAFC president Gilles Cottier said through the agreement SAFC will introduce its technologies to the South Korea market.
"As the drug discovery and development process becomes increasingly complex and expensive, we feel that our pre-formulation services are well-positioned to help pharmaceutical and biopharmaceutical companies around the globe to accelerate their pipelines," Cottier added.
SAFC is a custom manufacturing and services business unit of Sigma-Aldrich Corporation.
